Spectrum Acquiring Allos on Heels of Apaziquone Failure

It was a tumultuous day at the market for Spectrum Pharmaceuticals Inc. and Allos Therapeutics Inc., as investors responded simultaneously to news of the two companies' merger and the failure of Spectrum's cancer drug apaziquone in two Phase III trials.